Prescient Therapeutics Limited (AU:PTX) has released an update.
Prescient Therapeutics Limited reports a productive March quarter with a strong cash balance of $15.8 million and continued progress in their cancer therapy developments, including a promising Phase 1b study for PTX-100 in T-cell lymphomas. The company presented positive clinical data at a specialist conference, and while they are ceasing development of PTX-200 for AML due to a shifting treatment landscape, focus remains on advancing their innovative therapy pipeline.
For further insights into AU:PTX stock, check out TipRanks’ Stock Analysis page.
